| Previous close | 0.790 |
| Open | 0.795 |
| Bid | 0.790 x |
| Ask | 0.795 x |
| Day's range | 0.795 - 0.795 |
| 52-week range | 0.590 - 0.880 |
| Volume | 20,355 |
| Avg. volume | 223,838 |
| Market cap | 293.43M |
| Beta | 0.64 |
| PE ratio (TTM) | -12.62 |
| EPS (TTM) | -0.06 |
| Earnings date | N/A |
| Dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.94 |
- Business Wire•last month
Starpharma Sells Agrochemicals Business to Agrium for $35M
MELBOURNE, Australia--(BUSINESSWIRE)-- Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that it has completed a transaction to sell its agrochemicals and Priostar® business (Starpharma Agrochemicals) to Agrium, Inc., (Agrium) (NYSE: AGU, TSE: AGU) for A$35 million in cash consideration. The Starpharma Agrochemical business will be operated by Agrium’s wholly-owned subsidiary, Loveland Products, Inc. This business is independent of Starpharma’s DEP® and VivaGel® products and related intellectual property portfolios.
- Business Wire•3 months ago
Ansell Launches VivaGel® Condom in Canada
MELBOURNE, Australia--(BUSINESSWIRE)-- Starpharma Holdings Ltd (ASX:SPL, OTCQX:SPHRY) is pleased to announce the VivaGel ® condom has been launched in Canada by Ansell (ASX:ANN) under the LifeStyles ® ...
- Business Wire•6 months ago
VivaGel® BV granted QIDP and Fast Track designation by US FDA
MELBOURNE, Australia--(BUSINESSWIRE)-- Starpharma Holdings Ltd (ASX:SPL, OTCQX:SPHRY) today announced it has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designation for VivaGel® BV by the US Food and Drug Administration (FDA). QIDP and Fast Track designations were granted independently for both the VivaGel® BV treatment and prevention indications for bacterial vaginosis (BV). This positive development recognises the high unmet medical need in the management of BV and the potential of VivaGel® BV to address that need for both treatment and prevention of recurrent BV, markets estimated to be worth in excess of US$1 billion globally.
